Shares in U.S. lab Eli Lilly and Company (LLY) jumped 11.7 percent on Wall Street on Monday, ending a new record high at $185.94 after the release of positive clinical trial results for its experimental treatment for Alzheimer’s disease.
The results of the Phase 2 clinical trial showed that donanemab slowed the deterioration of cognitive and vital functions in the early stages of the disease by about one third. Donanemab is an experimental antibody that aims to remove deposits in the brain from a beta-amyloid protein called N3pG, believed to play an important role in Alzheimer’s disease.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
The study showed that treatment resulted in a significant slowdown in the decline in cognitive and daily life functions in patients with early-stage Alzheimer’s disease. Compared to placebo, donanemab slowed the decline of patients by 32%, thus meeting its goals, said Eli Lilly.
The study also confirmed that the presence of beta-amyloid protein deposits in the brain is an important accelerator of Alzheimer’s disease, although other factors are involved in this little-known disease.
Donanemab from Lilly shares the same class to aducanumab, Biogen’s candidate currently under review by the Food and Drug Administration (FDA) and is set to be decided by the authority on March 7 whether to approve it. Beta amyloid, which has become a very controversial target for drug researchers seeking to find out how best to help patients with Alzheimer’s disease, is the subject of these treatment candidates.
The news from Eli Lilly and Company (LLY) arrived in parallel with the annual J.P. Morgan Healthcare Meeting, an annual pharmaceutical gathering event well-known for spectacular presentations.